期刊
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.637239
关键词
CD73; VEGF; adipose derived mesenchymal stem cells; angiogenesis; myocardial infarction
资金
- National Natural Science Foundation of China [81400237]
- Science and Technology Project in Henan Province [202102310050]
- Zhengzhou Key Laboratory of Cardiac Structure [2019KFKT003]
- Research Projects of Xinxiang Medical University [2017CXY-2-8]
- The 12th Five-Year Plan of Educational Science in Henan Province [2015-JKGHYB-0079]
- National College Students' Innovation and Entrepreneurship Training Program in 2019 [S201910472026]
The research demonstrates the effective role of CD73(+) AD-MSCs in treating myocardial infarction by promoting angiogenesis for accelerating cardiac recovery. This subgroup shows differences in the expression of factors like VEGF compared to other subgroups, suggesting its potential superiority in myocardial repair.
With multipotent differentiation potential and paracrine capacity, mesenchymal stem cells (MSCs) have been widely applied in clinical practice for the treatment of ischemic heart disease. MSCs are a heterogeneous population and the specific population of MSCs may exhibit a selective ability for tissue repair. The aim of our research was to adapt the CD73(+) subgroup of adipose derived MSCs (AD-MSCs) for the therapy of myocardial infarction (MI). In this research, AD-MSCs were isolated from adipose tissue surrounding the groin of mice and CD73(+) AD-MSCs were sorted using flow cytometry. To investigate the therapeutic effects of CD73(+) AD-MSCs, 1.2 x 10(6) CD73(+) AD-MSCs were transplanted into rat model of MI, and CD73(-) AD-MSCs, normal AD-MSCs transplantation served as control. Our results revealed that CD73(+) AD-MSCs played a more effective role in the acceleration function of cardiac recovery by promoting angiogenesis in a rat model of MI compared with mixed AD-MSCs and CD73(-) AD-MSCs. Moreover, with the expression of CD73 in AD-MSCs, the secretion of VEGF, SDF-1 alpha, and HGF factors could be promoted. It also shows differences between CD73(+) and CD73(-) AD-MSCs when the transcription profiles of these two subgroups were compared, especially in VEGF pathway. These findings raise an attractive outlook on CD73(+) AD-MSCs as a dominant subgroup for treating MI-induced myocardial injury. CD73, a surface marker, can be used as a MSCs cell quality control for the recovery of MI by accelerating angiogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据